Újdonságok a gyermekkori non-Hodgkinlimfóma kezelésében és kivizsgálásában. Szakirodalmi áttekintés és a debreceni gyermekhematológiai központ adatai

István Szegedi, Imre Gáspár, Katalin Gyurina, Zsuzsa Zele, C. Kiss

Research output: Article

Abstract

Classification, staging and treatment response criteria of pediatric NHL have been revised. Long-term survival reaches ~90% at the expense of severe acute toxicities. The outcome of refractory and relapsed cases is poor. The small number of patients hinders introduction of targeted therapies. Here we summarize principles and perspectives of pediatric NHL supported by results of a retrospective clinical survey. Twenty-five patients (21 boys, 4 girls; mean age: 11.9 years) were registered between 2009 and 2018: 11 Burkitt lymphomas, 4 diffuse large B-cell lymphomas, 5 T-cell lymphoblastic lymphomas, and 1-1 grey-zone lymphoma, anaplastic large-cell lymphoma, cutaneous T-cell lymphoma, angioimmunoblastic lymphoma, and Castleman disease. Remission rate was 22/25, 20/25 patients survived (mean follow-up time: 3.9 years). Chemotherapies according to NHL-BFM 95, CHOP, FAB/LMB96, Inter-B-NHL Ritux 2010, Euro-LB02, and ALCL99 were applied. Adjuvant immunotherapy was applied in patients with mature B-cell NHL (rituximab in 7 cases, obinutuzumab in 2 relapsed cases). In Castleman disease siltuximab was applied.

Original languageHungarian
Pages (from-to)204-213
Number of pages10
JournalMagyar Onkologia
Volume62
Issue number4
Publication statusPublished - dec. 12 2018

Fingerprint

Non-Hodgkin's Lymphoma
Pediatrics
Giant Lymph Node Hyperplasia
Lymphoma
B-Lymphocytes
Anaplastic Large-Cell Lymphoma
Cutaneous T-Cell Lymphoma
Burkitt Lymphoma
T-Cell Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Immunotherapy
Drug Therapy
Survival
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Újdonságok a gyermekkori non-Hodgkinlimfóma kezelésében és kivizsgálásában. Szakirodalmi áttekintés és a debreceni gyermekhematológiai központ adatai. / Szegedi, István; Gáspár, Imre; Gyurina, Katalin; Zele, Zsuzsa; Kiss, C.

In: Magyar Onkologia, Vol. 62, No. 4, 12.12.2018, p. 204-213.

Research output: Article

@article{98becfddd64b470b8f47c08ae4454301,
title = "{\'U}jdons{\'a}gok a gyermekkori non-Hodgkinlimf{\'o}ma kezel{\'e}s{\'e}ben {\'e}s kivizsg{\'a}l{\'a}s{\'a}ban. Szakirodalmi {\'a}ttekint{\'e}s {\'e}s a debreceni gyermekhematol{\'o}giai k{\"o}zpont adatai",
abstract = "Classification, staging and treatment response criteria of pediatric NHL have been revised. Long-term survival reaches ~90{\%} at the expense of severe acute toxicities. The outcome of refractory and relapsed cases is poor. The small number of patients hinders introduction of targeted therapies. Here we summarize principles and perspectives of pediatric NHL supported by results of a retrospective clinical survey. Twenty-five patients (21 boys, 4 girls; mean age: 11.9 years) were registered between 2009 and 2018: 11 Burkitt lymphomas, 4 diffuse large B-cell lymphomas, 5 T-cell lymphoblastic lymphomas, and 1-1 grey-zone lymphoma, anaplastic large-cell lymphoma, cutaneous T-cell lymphoma, angioimmunoblastic lymphoma, and Castleman disease. Remission rate was 22/25, 20/25 patients survived (mean follow-up time: 3.9 years). Chemotherapies according to NHL-BFM 95, CHOP, FAB/LMB96, Inter-B-NHL Ritux 2010, Euro-LB02, and ALCL99 were applied. Adjuvant immunotherapy was applied in patients with mature B-cell NHL (rituximab in 7 cases, obinutuzumab in 2 relapsed cases). In Castleman disease siltuximab was applied.",
author = "Istv{\'a}n Szegedi and Imre G{\'a}sp{\'a}r and Katalin Gyurina and Zsuzsa Zele and C. Kiss",
year = "2018",
month = "12",
day = "12",
language = "Hungarian",
volume = "62",
pages = "204--213",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "4",

}

TY - JOUR

T1 - Újdonságok a gyermekkori non-Hodgkinlimfóma kezelésében és kivizsgálásában. Szakirodalmi áttekintés és a debreceni gyermekhematológiai központ adatai

AU - Szegedi, István

AU - Gáspár, Imre

AU - Gyurina, Katalin

AU - Zele, Zsuzsa

AU - Kiss, C.

PY - 2018/12/12

Y1 - 2018/12/12

N2 - Classification, staging and treatment response criteria of pediatric NHL have been revised. Long-term survival reaches ~90% at the expense of severe acute toxicities. The outcome of refractory and relapsed cases is poor. The small number of patients hinders introduction of targeted therapies. Here we summarize principles and perspectives of pediatric NHL supported by results of a retrospective clinical survey. Twenty-five patients (21 boys, 4 girls; mean age: 11.9 years) were registered between 2009 and 2018: 11 Burkitt lymphomas, 4 diffuse large B-cell lymphomas, 5 T-cell lymphoblastic lymphomas, and 1-1 grey-zone lymphoma, anaplastic large-cell lymphoma, cutaneous T-cell lymphoma, angioimmunoblastic lymphoma, and Castleman disease. Remission rate was 22/25, 20/25 patients survived (mean follow-up time: 3.9 years). Chemotherapies according to NHL-BFM 95, CHOP, FAB/LMB96, Inter-B-NHL Ritux 2010, Euro-LB02, and ALCL99 were applied. Adjuvant immunotherapy was applied in patients with mature B-cell NHL (rituximab in 7 cases, obinutuzumab in 2 relapsed cases). In Castleman disease siltuximab was applied.

AB - Classification, staging and treatment response criteria of pediatric NHL have been revised. Long-term survival reaches ~90% at the expense of severe acute toxicities. The outcome of refractory and relapsed cases is poor. The small number of patients hinders introduction of targeted therapies. Here we summarize principles and perspectives of pediatric NHL supported by results of a retrospective clinical survey. Twenty-five patients (21 boys, 4 girls; mean age: 11.9 years) were registered between 2009 and 2018: 11 Burkitt lymphomas, 4 diffuse large B-cell lymphomas, 5 T-cell lymphoblastic lymphomas, and 1-1 grey-zone lymphoma, anaplastic large-cell lymphoma, cutaneous T-cell lymphoma, angioimmunoblastic lymphoma, and Castleman disease. Remission rate was 22/25, 20/25 patients survived (mean follow-up time: 3.9 years). Chemotherapies according to NHL-BFM 95, CHOP, FAB/LMB96, Inter-B-NHL Ritux 2010, Euro-LB02, and ALCL99 were applied. Adjuvant immunotherapy was applied in patients with mature B-cell NHL (rituximab in 7 cases, obinutuzumab in 2 relapsed cases). In Castleman disease siltuximab was applied.

UR - http://www.scopus.com/inward/record.url?scp=85058611449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058611449&partnerID=8YFLogxK

M3 - Article

VL - 62

SP - 204

EP - 213

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 4

ER -